“…salbutamol, by intravenous administration are currently used in the treatment of severe asthma (Fitchett, McNicol & Riordan, 1975;Marlin & Turner, 1975a & b;Williams, Parrish & Seaton, 1975), cardiovascular shock (Wyse, Gibson & Branthwaite, 1974) and premature labour (Liggins & Vaughan, 1973;Korda, Lineham & Jones, 1974). Numerous metabolic effects including insulin release, hypokalaemia, lipolysis and glycogenolysis, which have important clinical implications, have been reported with salbutamol in animals (Loubatieres, Mariani, Sorel & Savi, 1971) and man (Goldberg, van As, Joffe, Krut, Bersohn & Seftel, 1975;Massara, Fassio, Camanni & Molinatti, 1975;Leitch, Clancy, Costello & Flenley, 1976;Taylor, Gaddie, Murchison & Palmer, 1976;Wang & Clansen, 1976). Although insulin release is mediated by stimulation of pancreatic 3-adrenoceptors (Porte, 1967;Imura, Kato, Ikeda, Morimoto & Yawata, 1971;Loubatieres et al, 1971;Goldberg et al, 1975), the subtype of f-adrenoceptor, i.e.…”